Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female subjects, who have signed the informed consent form must meet all of the following criteria~  1. 18 to 45 years of age~ 2. Body mass index (BMI) \> 19 and \< 0 kg/m2~ 3. Normal ECG, vital signs and laboratory test results~ 4. Use of effective birth control method and abstinence from sex~ 5. Negative pregnancy test and drug screen~Exclusion Criteria:~* Subjects with any of the following characteristics will be considered ineligible:~  1. History of clinically significant renal, hepatic pulmonary, cardiovascular, cerebrovascular, gastrointestinal, metabolic, hematological, endocrine, urological, immunological, neurologic or psychiatric disorders or connective tissue disease~ 2. Positive for human immunodeficiency virus (HIV), Hepatitis B, or surface antigen (HBsAg) or Hepatitis C antibody, tuberculosis (TB)~ 3. Current drug or alcohol addiction~ 4. History of clinically significant allergy of any kind~ 5. Prior use of IL-12 or HemaMax~ 6. Use of any approved or investigational biologic agents or vaccinations of any kind in last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HemaMax (Type: EXPERIMENTAL): Single subcutaneous 12 microgram dose of HemaMax
- Placebo (Type: PLACEBO_COMPARATOR): Single subcutaneous dose

Based on this trial design, predict the completion outcome and termination type (if applicable).